MYNZ
Mainz Biomed N.V. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website mainzbiomed.com
- Employees(FY) 58
- ISIN NL0015000LC2
Performance
-18.17%
1W
-33.94%
1M
-21.48%
3M
-76.92%
6M
-37.93%
YTD
-85.71%
1Y
Profile
Mainz Biomed N.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics. It offers ColoAlert, a colorectal cancer screening stool-based deoxyribonucleic acid test; and PancAlert, a product candidate for a pancreatic cancer screening test. The company has a research collaboration with Microba Life Sciences to discover and develop novel therapeutics for major diseases. The company was founded in 2008 and is based in Mainz, Germany.
Technical Analysis of MYNZ 2024-05-03
Overview:
In analyzing the technical indicators for MYNZ over the last 5 days, we will delve into the trends, momentum, volatility, and volume aspects to provide a comprehensive outlook on the possible stock price movement. By examining key indicators such as moving averages, MACD, RSI, Bollinger Bands, and OBV, we aim to offer valuable insights...
Recent News & Updates
- 2024-05-06 20:01
- 2024-04-29 00:02
mRNA Is Promising A Breakthrough In Fighting Cancer(Yahoo Finance)
- 2024-04-24 21:29
- 2024-04-10 00:47
- 2024-04-09 09:53
- 2024-04-08 20:01
Mainz Biomed Reports Full Year 2023 Financial Results(Globenewswire)
- 2024-03-18 20:01
- 2024-03-17 20:01
- 2024-03-11 20:01
- 2024-03-07 23:00
- 2024-03-04 19:01
- 2024-02-27 23:54
- 2024-02-26 19:01
- 2024-02-22 01:21
- 2024-02-21 19:01
- 2024-02-20 19:01
- 2024-02-06 23:13
- 2024-02-05 19:01
- 2024-02-01 03:17
- 2024-01-10 19:01
- 2024-01-09 02:40
2024 Marks a New Era Of Pharmaceutical Innovation(Yahoo Finance)
- 2024-01-08 19:01
Mainz Biomed Provides Year-End Corporate Review 2023(Globenewswire)
- 2023-12-29 01:48
- 2023-12-18 19:01
- 2023-12-11 19:01
- 2023-12-05 01:06
- 2023-12-04 20:01
- 2023-11-28 19:01
- 2023-11-19 19:01
- 2023-11-15 19:01
Page 1 of 4
previousnext